|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
GB8918616D0
(en)
|
1989-08-15 |
1989-09-27 |
Univ Glasgow |
Herpes simplex virus type 1 mutant
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
JP3540315B2
(ja)
|
1991-09-23 |
2004-07-07 |
メディカル リサーチ カウンシル |
キメラ抗体の製造−組合せアプローチ
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
DE69334275D1
(de)
|
1992-08-21 |
2009-05-20 |
Univ Bruxelles |
Immunoglobuline ohne Leichtkette
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
WO1994025591A1
(en)
|
1993-04-29 |
1994-11-10 |
Unilever N.V. |
PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
GB9415319D0
(en)
|
1994-07-29 |
1994-09-21 |
Medical Res Council |
HSV viral vector
|
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US6093570A
(en)
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
EP1002119A1
(en)
|
1997-07-31 |
2000-05-24 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeted hsv vectors
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
FR2777909B1
(fr)
|
1998-04-24 |
2002-08-02 |
Pasteur Institut |
Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
US6692736B2
(en)
|
2000-03-24 |
2004-02-17 |
Cell Genesys, Inc. |
Cell-specific adenovirus vectors comprising an internal ribosome entry site
|
|
US7465583B2
(en)
|
2000-06-01 |
2008-12-16 |
The University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
WO2002088346A2
(en)
|
2001-05-01 |
2002-11-07 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
WO2009095742A1
(en)
|
2008-01-31 |
2009-08-06 |
Cellectis |
New i-crei derived single-chain meganuclease and uses thereof
|
|
US20060206949A1
(en)
|
2003-01-28 |
2006-09-14 |
Sylvain Arnould |
Custom-made meganuclease and use thereof
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
FR2872170B1
(fr)
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
|
EP1828390B1
(en)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
ES2422291T3
(es)
|
2007-10-31 |
2013-09-10 |
Prec Biosciences Inc |
Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
EP2396343B1
(en)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
WO2010093966A2
(en)
|
2009-02-12 |
2010-08-19 |
Fred Hutchinson Cancer Research Center |
Generation of a dna nicking enzyme that stimulates site-specific gene conversion from a homing endonuclease
|
|
WO2011016238A1
(en)
*
|
2009-08-06 |
2011-02-10 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to a beta oligomers and use thereof
|
|
AU2010325563B2
(en)
|
2009-11-27 |
2017-02-02 |
Basf Plant Science Company Gmbh |
Chimeric endonucleases and uses thereof
|
|
US9169494B2
(en)
|
2010-01-12 |
2015-10-27 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
|
WO2011097456A2
(en)
|
2010-02-05 |
2011-08-11 |
The University Of North Carolina At Chapel Hill |
Compositions and methods for enhanced parvovirus transduction
|
|
WO2011156430A2
(en)
|
2010-06-07 |
2011-12-15 |
Fred Hutchinson Cancer Research Center |
Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof
|
|
SG189482A1
(en)
|
2010-10-27 |
2013-05-31 |
Cellectis |
Method for increasing the efficiency of double-strand break-induced mutagenesis
|
|
US8673557B2
(en)
|
2011-02-28 |
2014-03-18 |
Seattle Children's Research Institute |
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
|
|
US20140115726A1
(en)
|
2011-04-05 |
2014-04-24 |
Cellectis |
New tale-protein scaffolds and uses thereof
|
|
BR112013030652A2
(pt)
|
2011-06-10 |
2016-12-13 |
Basf Plant Science Co Gmbh |
polinucleotídeo que codifica um polipeptídeo, molécula de ácido nucleico, vetor, organismo não humano, polipeptídeo e método para introduzir um ácido nucleico de interesse em um genoma de um organismo não humano
|
|
US9382319B2
(en)
|
2011-09-26 |
2016-07-05 |
Jn Biosciences Llc |
Hybrid constant regions
|
|
EP2760891B1
(en)
|
2011-09-26 |
2018-11-07 |
JN Biosciences LLC |
Hybrid constant regions
|
|
US8450107B1
(en)
|
2011-11-30 |
2013-05-28 |
The Broad Institute Inc. |
Nucleotide-specific recognition sequences for designer TAL effectors
|
|
EP2836226B1
(en)
|
2012-02-24 |
2017-06-28 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for the treatment of hemoglobinopathies
|
|
JP6608807B2
(ja)
|
2013-05-29 |
2019-11-20 |
セレクティス |
Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
|
|
CA2913872C
(en)
|
2013-05-31 |
2022-01-18 |
Cellectis |
A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof
|
|
CA2913871C
(en)
|
2013-05-31 |
2021-07-13 |
Cellectis |
A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof
|
|
DK3105317T3
(en)
|
2014-02-14 |
2019-01-14 |
Cellectis |
Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
|
|
SG11201608701QA
(en)
|
2014-04-18 |
2016-11-29 |
Editas Medicine Inc |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
WO2015164759A2
(en)
|
2014-04-25 |
2015-10-29 |
Bluebird Bio, Inc. |
Mnd promoter chimeric antigen receptors
|
|
RS61406B1
(sr)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio Inc |
Poboljšane kompozicije t ćelija
|
|
CA3081058C
(en)
*
|
2015-01-16 |
2024-02-20 |
Academia Sinica |
Linker units and their uses in configuring pharmaceutical molecules
|
|
AU2016274989A1
(en)
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
|
JP7033453B2
(ja)
|
2015-06-30 |
2022-03-10 |
セレクティス |
特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
AU2017235657B2
(en)
|
2016-03-18 |
2022-07-21 |
Fred Hutchinson Cancer Center |
Compositions and methods for CD20 immunotherapy
|
|
US20190112380A1
(en)
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
CN105949317B
(zh)
|
2016-04-12 |
2019-07-02 |
上海优卡迪生物医药科技有限公司 |
抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
EP3336107A1
(en)
*
|
2016-12-15 |
2018-06-20 |
Miltenyi Biotec GmbH |
Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
|
|
IL270776B2
(en)
|
2017-05-25 |
2024-11-01 |
Bluebird Bio Inc |
Cblb endonuclease variants, compositions, and methods of use
|
|
MA51428A
(fr)
|
2017-12-22 |
2020-11-04 |
Bluebird Bio Inc |
Récepteur d'antigène chimérique multivalent
|
|
CN112368021B
(zh)
|
2018-06-14 |
2025-02-21 |
2赛文缇生物公司 |
Cd79a嵌合抗原受体
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
MX2021015495A
(es)
*
|
2019-06-14 |
2022-04-18 |
2Seventy Bio Inc |
Composiciones y métodos para tratar cáncer.
|